Jennison Associates LLC lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 77.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,547,683 shares of the company’s stock after purchasing an additional 1,113,992 shares during the period. Jennison Associates LLC owned about 3.81% of Crinetics Pharmaceuticals worth $90,647,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently bought and sold shares of CRNX. FMR LLC increased its position in shares of Crinetics Pharmaceuticals by 97.7% in the third quarter. FMR LLC now owns 2,140,861 shares of the company’s stock valued at $63,669,000 after buying an additional 1,057,947 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Crinetics Pharmaceuticals by 24.7% during the third quarter. Vanguard Group Inc. now owns 3,407,035 shares of the company’s stock valued at $101,325,000 after purchasing an additional 674,301 shares in the last quarter. Avidity Partners Management LP acquired a new stake in shares of Crinetics Pharmaceuticals in the third quarter valued at about $18,141,000. Eventide Asset Management LLC increased its stake in shares of Crinetics Pharmaceuticals by 134.3% during the third quarter. Eventide Asset Management LLC now owns 1,018,782 shares of the company’s stock worth $30,299,000 after purchasing an additional 584,014 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Crinetics Pharmaceuticals during the third quarter worth about $13,383,000. Institutional investors and hedge funds own 98.51% of the company’s stock.
Insider Buying and Selling
In other Crinetics Pharmaceuticals news, CEO Richard Scott Struthers sold 40,951 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the completion of the sale, the chief executive officer now owns 237,835 shares of the company’s stock, valued at $11,694,346.95. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Marc Wilson sold 6,942 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $42.91, for a total value of $297,881.22. Following the sale, the chief financial officer now directly owns 110,630 shares of the company’s stock, valued at approximately $4,747,133.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Richard Scott Struthers sold 40,951 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the transaction, the chief executive officer now directly owns 237,835 shares of the company’s stock, valued at approximately $11,694,346.95. The disclosure for this sale can be found here. Over the last three months, insiders sold 190,216 shares of company stock worth $8,621,177. Company insiders own 7.00% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on CRNX
Crinetics Pharmaceuticals Price Performance
Shares of CRNX opened at $43.44 on Tuesday. Crinetics Pharmaceuticals, Inc. has a 12-month low of $15.76 and a 12-month high of $49.58. The firm has a 50-day moving average price of $42.50 and a 200 day moving average price of $36.36.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.01). Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative return on equity of 52.93%. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.84) earnings per share. On average, sell-side analysts anticipate that Crinetics Pharmaceuticals, Inc. will post -3.34 earnings per share for the current year.
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Featured Stories
- Five stocks we like better than Crinetics Pharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- Sherwin-William’s Win Over PPG Stock in The Construction Boom
- What is an Earnings Surprise?
- Zscaler’s Potential Upside Continues to Explode
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 A.I. Stocks to Watch Out For Not Named NVIDIA
Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report).
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.